본문 바로가기

KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널
Experimental and Molecular Medicine38(5) · pp.502 · 2006
피인용
Web of Science 13KCI 4
ISSN
1226-3613

저자

  1. 이의연제1저자부산대학교
  2. 박시영부산대학교
  3. 송현석성균관대학교
  4. 손명진성균관대학교
  5. 이규양한국화학연구원
  6. 유성은충남대학교
  7. 김영진교신저자부산대학교

초록

Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angio genesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new benzopyran derivative, has anti-angiogenic activities. KR-31831 inhibited the proliferation, migration, invasion and tube formation of bovine aortic endothelial cells (BAECs), and suppressed the release of matrix metalloproteinase-2 (MMP-2) of BAECs. KR-31831 also inhibited in vivo angiogenesis in mouse Matrigel plug assay. Furthermore, the mRNA expressions of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor-2 (FGFR-2), and vascular endothelial growth factor receptor-2 (VEGFR-2) were decreased by KR-31831. Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers.

식별자

WoS UID
000241927500006
KCI
ART001100047